Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 2/2020

Open Access 01-04-2020 | Positron Emission Tomography | Review Article

Quantitative Rodent Brain Receptor Imaging

Authors: Kristina Herfert, Julia G. Mannheim, Laura Kuebler, Sabina Marciano, Mario Amend, Christoph Parl, Hanna Napieczynska, Florian M. Maier, Salvador Castaneda Vega, Bernd J. Pichler

Published in: Molecular Imaging and Biology | Issue 2/2020

Login to get access

Abstract

Positron emission tomography (PET) is a non-invasive imaging technology employed to describe metabolic, physiological, and biochemical processes in vivo. These include receptor availability, metabolic changes, neurotransmitter release, and alterations of gene expression in the brain. Since the introduction of dedicated small-animal PET systems along with the development of many novel PET imaging probes, the number of PET studies using rats and mice in basic biomedical research tremendously increased over the last decade. This article reviews challenges and advances of quantitative rodent brain imaging to make the readers aware of its physical limitations, as well as to inspire them for its potential applications in preclinical research. In the first section, we briefly discuss the limitations of small-animal PET systems in terms of spatial resolution and sensitivity and point to possible improvements in detector development. In addition, different acquisition and post-processing methods used in rodent PET studies are summarized. We further discuss factors influencing the test-retest variability in small-animal PET studies, e.g., different receptor quantification methodologies which have been mainly translated from human to rodent receptor studies to determine the binding potential and changes of receptor availability and radioligand affinity. We further review different kinetic modeling approaches to obtain quantitative binding data in rodents and PET studies focusing on the quantification of endogenous neurotransmitter release using pharmacological interventions. While several studies have focused on the dopamine system due to the availability of several PET tracers which are sensitive to dopamine release, other neurotransmitter systems have become more and more into focus and are described in this review, as well. We further provide an overview of latest genome engineering technologies, including the CRISPR/Cas9 and DREADD systems that may advance our understanding of brain disorders and function and how imaging has been successfully applied to animal models of human brain disorders. Finally, we review the strengths and opportunities of simultaneous PET/magnetic resonance imaging systems to study drug-receptor interactions and challenges for the translation of PET results from bench to bedside.
Literature
1.
2.
3.
Koprich JB, Kalia LV, Brotchie JM (2017) Animal models of alpha-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci 18:515–529PubMedCrossRef
4.
Pouladi MA, Morton AJ, Hayden MR (2013) Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci 14:708–721PubMedCrossRef
5.
Chadman KK (2017) Animal models for autism in 2017 and the consequential implications to drug discovery. Expert Opin Drug Discov 12:1187–1194PubMedCrossRef
6.
Nielsen J, Fejgin K, Sotty F et al (2017) A mouse model of the schizophrenia-associated 1q21.1 microdeletion syndrome exhibits altered mesolimbic dopamine transmission. Transl Psychiatry 7:1261PubMedPubMedCentralCrossRef
7.
8.
Cherry SR (2001) Fundamentals of positron emission tomography and applications in preclinical drug development. J Clin Pharmacol 41:482–491PubMedCrossRef
9.
Cherry SR, Gambhir SS (2001) Use of positron emission tomography in animal research. ILAR J 42:219–232PubMedCrossRef
10.
Fang XT, Eriksson J, Antoni G et al (2017) Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [11C]ABP688 PET imaging and ex vivo immunoblotting. Neuropharmacology 113:293–300PubMedCrossRef
11.
Walker M, Ehrlichmann W, Stahlschmidt A et al (2016) In vivo evaluation of 11C-DASB for quantitative SERT imaging in rats and mice. J Nucl Med 57:115–121PubMedCrossRef
12.
Fischer K, Sossi V, Schmid A et al (2011) Noninvasive nuclear imaging enables the in vivo quantification of striatal dopamine receptor expression and raclopride affinity in mice. J Nucl Med 52:1133–1141PubMedCrossRef
13.
Fischer K, Sossi V, von Ameln-Mayerhofer A, Reischl G, Pichler BJ (2012) In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET. Neuroimage 59:2413–2422PubMedCrossRef
14.
Sossi V, Dinelle K, Jivan S et al (2012) In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET. J Nucl Med 53:813–822PubMedCrossRef
15.
Phan JA, Landau AM, Jakobsen S, Gjedde A (2017) Radioligand binding analysis of alpha 2 adrenoceptors with [11C]yohimbine in brain in vivo: extended inhibition plot correction for plasma protein binding. Sci Rep-UK 7:15979CrossRef
16.
Virdee K, Cumming P, Caprioli D et al (2012) Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders. Neurosci Biobehav Rev 36:1188–1216PubMedCrossRef
17.
18.
19.
Goertzen AL, Bao Q, Bergeron M et al (2012) NEMA NU 4-2008 comparison of preclinical PET imaging systems. J Nucl Med 53:1300–1309PubMedCrossRef
20.
Nagy K, Toth M, Major P et al (2013) Performance evaluation of the small-animal nanoScan PET/MRI system. J Nucl Med 54:1825–1832PubMedCrossRef
21.
22.
Mannheim JG, Schmid AM, Schwenck J et al (2018) PET/MRI hybrid systems. Semin Nucl Med 48:332–347PubMedCrossRef
23.
Badea A, Ali-Sharief AA, Johnson GA (2007) Morphometric analysis of the C57BL/6J mouse brain. Neuroimage 37:683–693PubMedCrossRef
24.
Ma Y, Hof PR, Grant SC et al (2005) A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Neuroscience 135:1203–1215PubMedCrossRef
25.
Lin YS, Wang HY, Huang DF et al (2016) Neuronal splicing regulator RBFOX3 (NeuN) regulates adult hippocampal neurogenesis and synaptogenesis. PLoS One 11:e0164164PubMedPubMedCentralCrossRef
26.
Hume SP, Jones T (1998) Positron emission tomography (PET) methodology for small animals and its application in radiopharmaceutical preclinical investigation. Nucl Med Biol 25:729–732PubMedCrossRef
27.
Moses WW (2011) Fundamental limits of spatial resolution in PET. Nucl Instrum Methods A 648:S236–S240CrossRef
28.
Kolb A, Parl C, Mantlik F et al (2014) Development of a novel depth of interaction PET detector using highly multiplexed G-APD cross-strip encoding. Med Phys 41:081916PubMedCrossRef
29.
Kang HG, Hong SJ, Ko GB et al (2015) Assessment of MR-compatibility of SiPM PET insert using short optical fiber bundles for small animal research. J Instrum 10:P12008–P12008CrossRef
30.
Ko GB, Yoon HS, Kim KY et al (2016) Simultaneous multiparametric PET/MRI with silicon photomultiplier PET and ultra-high-field MRI for small-animal imaging. J Nucl Med 57:1309–1315PubMedCrossRef
31.
Olcott P, Kim E, Hong K et al (2015) Prototype positron emission tomography insert with electro-optical signal transmission for simultaneous operation with MRI. Phys Med Biol 60:3459–3478PubMedCrossRef
32.
Catana C, Wu Y, Judenhofer MS, Qi J, Pichler BJ, Cherry SR (2006) Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. J Nucl Med 47:1968–1976PubMed
33.
Maramraju SH, Smith SD, Junnarkar SS et al (2011) Small animal simultaneous PET/MRI: initial experiences in a 9.4 T microMRI. Phys Med Biol 56:2459–2480PubMedCrossRef
34.
Wehrl HF, Schwab J, Hasenbach K et al (2013) Multimodal elucidation of choline metabolism in a murine glioma model using magnetic resonance spectroscopy and 11C-choline positron emission tomography. Cancer Res 73:1470–1480PubMedCrossRef
35.
Weissler B, Gebhardt P, Lerche CW et al (2014) MR compatibility aspects of a silicon photomultiplier-based PET/RF insert with integrated digitisation. Phys Med Biol 59:5119–5139PubMedCrossRef
36.
Yamamoto S, Watabe T, Watabe H et al (2012) Simultaneous imaging using Si-PM-based PET and MRI for development of an integrated PET/MRI system. Phys Med Biol 57:N1–N13PubMedCrossRef
37.
Yoon HS, Ko GB, Kwon SI et al (2012) Initial results of simultaneous PET/MRI experiments with an MRI-compatible silicon photomultiplier PET scanner. J Nucl Med 53:608–614PubMedCrossRef
38.
39.
Yao R, Lecomte R, Crawford ES (2012) Small-animal PET: what is it, and why do we need it? J Nucl Med Technol 40:157–165PubMedCrossRef
40.
41.
Jones T, Rabiner EA, Company PETRA (2012) The development, past achievements, and future directions of brain PET. J Cereb Blood Flow Metab 32:1426–1454PubMedPubMedCentralCrossRef
42.
Van Heertum RL, Masanori Ichise MDF, Tikofsky RS (2015) Functional cerebral SPECT and PET imaging. Wolters Kluwer Health, Philadelphia
43.
Burger C, Deschwanden A, Ametamey S et al (2010) Evaluation of a bolus/infusion protocol for 11C-ABP688, a PET tracer for mGluR5. Nucl Med Biol 37:845–851PubMedCrossRef
44.
Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158PubMedCrossRef
45.
Shi X, Li N, Ding H et al (2018) Comparison among reconstruction algorithms for quantitative analysis of 11C-acetate cardiac PET imaging. Contrast Media Mol Imaging 2018:9193403PubMedPubMedCentralCrossRef
46.
Morimoto T, Ito H, Takano A et al (2006) Effects of image reconstruction algorithm on neurotransmission PET studies in humans: comparison between filtered backprojection and ordered subsets expectation maximization. Ann Nucl Med 20:237–243PubMedCrossRef
47.
Vunckx K, Dupont P, Goffin K et al (2014) Voxel-based comparison of state-of-the-art reconstruction algorithms for 18F-FDG PET brain imaging using simulated and clinical data. Neuroimage 102(Pt 2):875–884PubMedCrossRef
48.
Thiyagarajan A, Rajasekaran PM, Subramanian K (2014) A quantitative assessment of PET brain image reconstruction using MAP and neural network based segmentation of CG algorithm. Int J Comput Inform Syst Indust Manag Appl 6:381–390
49.
50.
51.
52.
El Ali HH, Bodholdt RP, Jorgensen JT, Myschetzky R, Kjaer A (2012) Importance of attenuation correction (AC) for small animal PET imaging. Diagnostics 2:42–51PubMedPubMedCentralCrossRef
53.
Mannheim JG, Schmid AM, Pichler BJ (2017) Influence of Co-57 and CT transmission measurements on the quantification accuracy and partial volume effect of a small animal PET scanner. Mol Imaging Biol 19:825–836PubMedCrossRef
54.
Mannheim JG, Judenhofer MS, Schmid A et al (2012) Quantification accuracy and partial volume effect in dependence of the attenuation correction of a state-of-the-art small animal PET scanner. Phys Med Biol 57:3981–3993PubMedCrossRef
55.
56.
Rahmim A, Rousset O, Zaidi H (2007) Strategies for motion tracking and correction in PET. PET Clinics 2:251–266PubMedCrossRef
57.
Catana C, Benner T, van der Kouwe A et al (2011) MRI-assisted PET motion correction for neurologic studies in an integrated MR-PET scanner. J Nucl Med 52:154–161PubMedCrossRef
58.
Furst S, Grimm R, Hong I et al (2015) Motion correction strategies for integrated PET/MR. J Nucl Med 56:261–269PubMedCrossRef
59.
Wurslin C, Schmidt H, Martirosian P et al (2013) Respiratory motion correction in oncologic PET using T1-weighted MR imaging on a simultaneous whole-body PET/MR system. J Nucl Med 54:464–471PubMedCrossRef
60.
Schiffer WK, Mirrione MM, Biegon A, Alexoff DL, Patel V, Dewey SL (2006) Serial microPET measures of the metabolic reaction to a microdialysis probe implant. J Neurosci Methods 155:272–284PubMedCrossRef
61.
Mirrione MM, Schiffer WK, Fowler JS, Alexoff DL, Dewey SL, Tsirka SE (2007) A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage 38:34–42PubMedCrossRef
62.
Casteels C, Vermaelen P, Nuyts J et al (2006) Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. J Nucl Med 47:1858–1866PubMed
63.
Verhaeghe J, Wyffels L, Wyckhuys T et al (2014) Rat brain normalization templates for robust regional analysis of [11C]ABP688 positron emission tomography/computed tomography. Mol Imaging 13
64.
Vallez Garcia D, Casteels C, Schwarz AJ et al (2015) A standardized method for the construction of tracer specific PET and SPECT rat brain templates: validation and implementation of a toolbox. PLoS One 10:e0122363PubMedPubMedCentralCrossRef
65.
Mannheim JG, Wehrl HF, Judenhofer MS, Pichler BJ (2011) Small animal PET cameras—development, technology, PET/CT, PET/MRI. In Trends on the role of PET in drug development. World Sci, pp 289–317
66.
Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48:932–945PubMedCrossRef
67.
Hoffman EJ, Huang SC, Phelps ME (1979) Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 3:299–308PubMedCrossRef
68.
Muellauer J, Willimayer R, Goertzen AL et al (2013) 18F, 11C and 58Ga in small animal PET imaging. Evaluation of partial volume correction methods. Nuklearmedizin Nuclear Medicine 52:250–261PubMedCrossRef
69.
Disselhorst JA, Brom M, Laverman P et al (2010) Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med 51:610–617PubMedCrossRef
70.
Erlandsson K, Buvat I, Pretorius PH et al (2012) A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys Med Biol 57:R119–R159PubMedCrossRef
71.
Rousset OG, Ma Y, Evans AC (1998) Correction for partial volume effects in PET: principle and validation. J Nucl Med 39:904–911PubMed
72.
Hume SP, Opacka-Juffry J, Myers R et al (1995) Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. Synapse 21:45–53PubMedCrossRef
73.
Noguchi J, Zhang MR, Yanamoto K, Nakao R, Suzuki K (2008) In vitro binding of [11C]raclopride with ultrahigh specific activity in rat brain determined by homogenate assay and autoradiography. Nucl Med Biol 35:19–27PubMedCrossRef
74.
Kuwabara H, Chamroonrat W, Mathews W et al (2011) Evaluation of 11C-ABP688 and 18F-FPEB for imaging mGluR5 receptors in the human brain. J Nucl Med 52:390
75.
Elmenhorst D, Aliaga A, Bauer A, Rosa-Neto P (2012) Test-retest stability of cerebral mGluR5 quantification using [11C]ABP688 and positron emission tomography in rats. Synapse 66:552–560PubMedCrossRef
76.
77.
Aznavour N, Benkelfat C, Gravel P et al (2008) MicroPET imaging of 5-HT1A receptors in rat brain: a test–retest [18F]MPPF study. Eur J Nucl Med Mol Imaging 36:53PubMedCrossRef
78.
Avendano-Estrada A, Avila-Rodriguez MA (2018) Reference tissue models in the assessment of 11C-DTBZ binding to the VMAT2 in rat striatum: a test-retest reproducibility study. Synapse 72:e22029PubMedCrossRef
79.
Sijbesma JW, Zhou X, Vallez Garcia D et al (2016) Novel approach to repeated arterial blood sampling in small animal PET: application in a test-retest study with the adenosine A1 receptor ligand [11C]MPDX. Mol Imaging Biol 18:715–723PubMedPubMedCentralCrossRef
80.
Sephton SM, Herde AM, Mu L et al (2015) Preclinical evaluation and test–retest studies of [18F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5). Eur J Nucl Med Mol Imaging 42:128–137PubMedCrossRef
81.
Zhou X, de Vries E, Koole M, Dierckx R, Elsinga P (2015) In vivo evaluation of [11C]preladenant for imaging of adenosine A2A receptors in rat brain: kinetic modelling and test/retest variability. J Nucl Med 56:488CrossRef
82.
Alexoff DL, Vaska P, Marsteller D et al (2003) Reproducibility of 11C-raclopride binding in the rat brain measured with the microPET R4: effects of scatter correction and tracer specific activity. J Nucl Med 44:815–822PubMed
83.
Kroll T, Elmenhorst D, Weisshaupt A et al (2014) Reproducibility of non-invasive A1 adenosine receptor quantification in the rat brain using [18F]CPFPX and positron emission tomography. Mol Imaging Biol 16:699–709PubMedCrossRef
84.
Elmenhorst D, Kroll T, Wedekind F et al (2013) In vivo kinetic and steady-state quantification of 18F-CPFPX binding to rat cerebral A1 adenosine receptors: validation by displacement and autoradiographic experiments. J Nucl Med 54:1411–1419PubMedCrossRef
85.
van Berckel BN, Ossenkoppele R, Tolboom N et al (2013) Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med 54:1570–1576PubMedCrossRef
86.
Keyes JW Jr (1995) SUV: standard uptake or silly useless value? J Nucl Med 36:1836–1839PubMed
87.
88.
Lammertsma AA (2017) Forward to the past: the case for quantitative PET imaging. J Nucl Med 58:1019–1024PubMedCrossRef
89.
Lammertsma AA, Bench CJ, Hume SP et al (1996) Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16:42–52PubMedCrossRef
90.
Schmidt KC, Turkheimer FE (2002) Kinetic modeling in positron emission tomography. Quart J Nucl Med 46:70–85
91.
Gunn RN, Gunn SR, Turkheimer FE et al (2002) Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 22:1425–1439PubMedCrossRef
92.
Gunn RN, Gunn SR, Cunningham VJ (2001) Positron emission tomography compartmental models. J Cereb Blood Flow Metab 21:635–652PubMedCrossRef
93.
Koeppe RA, Holthoff VA, Frey KA et al (1991) Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735–744PubMedCrossRef
94.
Innis RB, Cunningham VJ, Delforge J et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539PubMedCrossRef
95.
Weber B, Burger C, Biro P, Buck A (2002) A femoral arteriovenous shunt facilitates arterial whole blood sampling in animals. Eur J Nucl Med Mol Imaging 29:319–323PubMedCrossRef
96.
Herfert K, Marciano S, Kuebler L et al (2019) Preclinical experimentation (neurology). In: Lewis JS, Windhorst AD, Zeglis BM (eds) Radiopharmaceutical chemistry. Springer, Berlin
97.
Napieczynska H, Kolb A, Katiyar P et al (2018) Impact of the AIF recording method on kinetic parameters in small animal PET. J Nucl Med 59:1159–1164PubMedCrossRef
98.
Kimura Y, Seki C, Hashizume N et al (2013) Novel system using microliter order sample volume for measuring arterial radioactivity concentrations in whole blood and plasma for mouse PET dynamic study. Phys Med Biol 58:7889–7903PubMedCrossRef
99.
Yee SH, Jerabek PA, Fox PT (2005) Non-invasive quantification of cerebral blood flow for rats by microPET imaging of 15O labelled water: the application of a cardiac time-activity curve for the tracer arterial input function. Nucl Med Commun 26:903–911PubMedCrossRef
100.
Fang YH, Muzic RF Jr (2008) Spillover and partial-volume correction for image-derived input functions for small-animal 18F-FDG PET studies. J Nucl Med 49:606–614PubMedCrossRef
101.
Cunningham VJ, Hume SP, Price GR et al (1991) Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro. J Cereb Blood Flow Metab 11:1–9PubMedCrossRef
102.
Finnema SJ, Nabulsi NB, Eid T et al (2016) Imaging synaptic density in the living human brain. Sci Transl Med 8:348ra396CrossRef
103.
Becker G, Warnier C, Serrano ME et al (2017) Pharmacokinetic characterization of [18F]UCB-H PET radiopharmaceutical in the rat brain. Mol Pharm 14:2719–2725PubMedCrossRef
104.
Lacan G, Plenevaux A, Rubins DJ et al (2008) Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies. Eur J Nucl Med Mol Imaging 35:2256–2266PubMedCrossRef
105.
Liow JS, Lu S, McCarron JA et al (2007) Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. Synapse 61:96–105PubMedCrossRef
106.
Kroll T, Elmenhorst D, Matusch A et al (2014) [18F]Altanserin and small animal PET: impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT(2)A receptor densities in the rat brain. Nucl Med Biol 41:1–9PubMedCrossRef
107.
Syvanen S, Lindhe O, Palner M et al (2009) Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 37:635–643PubMedCrossRef
108.
Elsinga PH, Hendrikse NH, Bart J et al (2005) Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol Imaging Biol 7:37–44PubMedCrossRef
109.
Tournier N, Cisternino S, Peyronneau MA et al (2012) Discrepancies in the P-glycoprotein-mediated transport of 18F-MPPF: a pharmacokinetic study in mice and non-human primates. Pharm Res 29:2468–2476PubMedCrossRef
110.
Kroll T, Elmenhorst D, Matusch A et al (2013) Suitability of [18F]altanserin and PET to determine 5-HT2A receptor availability in the rat brain: in vivo and in vitro validation of invasive and non-invasive kinetic models. Mol Imaging Biol 15:456–467PubMedCrossRef
111.
Riss PJ, Hong YT, Williamson D et al (2011) Validation and quantification of [18F]altanserin binding in the rat brain using blood input and reference tissue modeling. J Cereb Blood Flow Metab 31:2334–2342PubMedPubMedCentralCrossRef
112.
Sadzot B, Lemaire C, Maquet P et al (1995) Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls. J Cereb Blood Flow Metab 15:787–797PubMedCrossRef
113.
Skaddan MB, Sherman PS, Kilbourn MR (2001) The role of species-dependent metabolism in the regional brain retention of 18F-labeled muscarinic acetylcholine receptor ligands. Nucl Med Biol 28:753–759PubMedCrossRef
114.
Walker MD, Dinelle K, Kornelsen R et al (2013) In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET. J Cereb Blood Flow Metab 33:59–66PubMedCrossRef
115.
116.
Brown AK, Kimura Y, Zoghbi SS et al (2008) Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. J Nucl Med 49:2042–2048PubMedCrossRef
117.
Shetty HU, Zoghbi SS, Simeon FG et al (2008) Radiodefluorination of 3-fluoro-5-(2-(2-[18F](fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ([18F]SP203), a radioligand for imaging brain metabotropic glutamate subtype-5 receptors with positron emission tomography, occurs by glutathionylation in rat brain. J Pharmacol Exp Ther 327:727–735PubMedCrossRef
118.
Fischer K (2012) Thesis: Limits and possibilities of the in vivo quantification of the dopaminergic system in rats and mice using positron emission tomography. In Department of Preclinical Imaging and Radiopharmacy. Library: Eberhard-Karls University of Tuebingen, p 433
119.
Doudet DJ, Jivan S, Ruth TJ, Holden JE (2002) Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. Synapse 44:198–202PubMedCrossRef
120.
Holden JE, Jivan S, Ruth TJ, Doudet DJ (2002) In vivo receptor assay with multiple ligand concentrations: an equilibrium approach. J Cereb Blood Flow Metab 22:1132–1141PubMedCrossRef
121.
Ikoma Y, Watabe H, Hayashi T et al (2009) Quantitative evaluation of changes in binding potential with a simplified reference tissue model and multiple injections of [11C]raclopride. Neuroimage 47:1639–1648PubMedCrossRef
122.
Ikoma Y, Watabe H, Hayashi T et al (2010) Measurement of density and affinity for dopamine D2 receptors by a single positron emission tomography scan with multiple injections of [11C]raclopride. J CerebBlood Flow Metab 30:663–673CrossRef
123.
Delforge J, Spelle L, Bendriem B et al (1996) Quantitation of benzodiazepine receptors in human brain using the partial saturation method. J Nucl Med 37:5–11PubMed
124.
Leriche L, Bjorklund T, Breysse N et al (2009) Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. J Neurosci 29:1544–1553PubMedPubMedCentralCrossRef
125.
Wimberley CJ, Fischer K, Reilhac A et al (2014) A data driven method for estimation of B(avail) and appK(D) using a single injection protocol with [11C]raclopride in the mouse. Neuroimage 99:365–376PubMedCrossRef
126.
Wimberley C, Angelis G, Boisson F et al (2014) Simulation-based optimisation of the PET data processing for partial saturation approach protocols. Neuroimage 97:29–40PubMedCrossRef
127.
Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423–451PubMedCrossRef
128.
Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM (2010) Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow 30:1682–1706CrossRef
129.
Sahin G, Thompson LH, Lavisse S et al (2014) Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. PLoS One 9:e90759PubMedPubMedCentralCrossRef
130.
Houston GC, Hume SP, Hirani E et al (2004) Temporal characterisation of amphetamine-induced dopamine release assessed with [11C]raclopride in anaesthetised rodents. Synapse 51:206–212PubMedCrossRef
131.
Hume SP, Myers R, Bloomfield PM et al (1992) Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse 12:47–54PubMedCrossRef
132.
Kuczenski R, Segal DS (1999) Dynamic changes in sensitivity occur during the acute response to cocaine and methylphenidate. Psychopharmacol (Berl) 147:96–103CrossRef
133.
Laruelle M, Iyer RN, al-Tikriti MS et al (1997) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1–14PubMedCrossRef
134.
Skinbjerg M, Liow JS, Seneca N et al (2010) D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model. Neuroimage 50:1402–1407PubMedCrossRef
135.
Hwang DR, Kegeles LS, Laruelle M (2000) (-)-N-[(11)C]propyl-norapomorphine: a positron-labeled dopamine agonist for PET imaging of D2 receptors. Nucl Med Biol 27:533–539PubMedCrossRef
136.
Wilson AA, McCormick P, Kapur S et al (2005) Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48:4153–4160PubMedCrossRef
137.
Finnema SJ, Seneca N, Farde L et al (2005) A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey. Nucl Med Biol 32:353–360PubMedCrossRef
138.
Seneca N, Zoghbi SS, Skinbjerg M et al (2008) Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA. Synapse 62:756–763PubMedPubMedCentralCrossRef
139.
Galineau L, Wilson AA, Garcia A et al (2006) In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. Synapse 60:172–183PubMedCrossRef
140.
Narendran R, Mason NS, Laymon CM et al (2010) A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Therap 333:533–539CrossRef
141.
Jørgensen LM, Weikop P, Villadsen J et al (2016) Cerebral 5-HT release correlates with [11C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain. J Cereb Blood Flow Metab 37:425–434PubMedPubMedCentralCrossRef
142.
Jørgensen LM, Weikop P, Svarer C et al (2017) Cerebral serotonin release correlates with [11C ]AZ10419369 PET measures of 5-HT 1B receptor binding in the pig brain. J Cereb Blood Flow Metab 38:1243–1252PubMedPubMedCentralCrossRef
143.
Jorgensen LM, Weikop P, Svarer C et al (2017) Cerebral serotonin release correlates with [11C]AZ10419369 PET measures of 5-HT1B receptor binding in the pig brain. J Cereb Blood Flow Metab 38:1243–1252PubMedPubMedCentralCrossRef
144.
Landau AM, Doudet DJ, Jakobsen S (2012) Amphetamine challenge decreases yohimbine binding to α2 adrenoceptors in Landrace pig brain. Psychopharmacol 222:155–163CrossRef
145.
146.
Phan JA, Landau AM, Wong DF et al (2015) Quantification of [11C]yohimbine binding to alpha2 adrenoceptors in rat brain in vivo. J Cereb Blood Flow Metab 35:501–511PubMedPubMedCentralCrossRef
147.
148.
Sperlagh B, Vizi ES (2011) The role of extracellular adenosine in chemical neurotransmission in the hippocampus and basal ganglia: pharmacological and clinical aspects. Curr Top Med Chem 11:1034–1046PubMedPubMedCentralCrossRef
149.
Noguchi J, Ishiwata K, Furuta R et al (1997) Evaluation of carbon-11 labeled KF15372 and its ethyl and methyl derivatives as a potential CNS adenosine A1 receptor ligand. Nucl Med Biol 24:53–59PubMedCrossRef
150.
Holschbach MH, Olsson RA, Bier D et al (2002) Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX): a potent and selective A1-adenosine receptor antagonist for in vivo imaging. J Med Chem 45:5150–5156PubMedCrossRef
151.
Zhou X, Khanapur S, de Jong JR et al (2017) In vivo evaluation of [11C]preladenant positron emission tomography for quantification of adenosine A2A receptors in the rat brain. J Cereb Blood Flow Metab 37:577–589PubMedCrossRef
152.
Ishiwata K, Wang WF, Kimura Y et al (2003) Preclinical studies on [11C]TMSX for mapping adenosine A2A receptors by positron emission tomography. Ann Nucl Med 17:205–211PubMedCrossRef
153.
Moresco RM, Todde S, Belloli S et al (2005) In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. Eur J Nucl Med Mol Imaging 32:405–413PubMedCrossRef
154.
Elmenhorst D, Garibotto V, Prescher A, Bauer A (2011) Adenosine A(1) receptors in human brain and transfected CHO cells: inhibition of [3H]CPFPX binding by adenosine and caffeine. Neurosci Lett 487:415–420PubMedCrossRef
155.
Guo M, Gao ZG, Tyler R et al (2018) Preclinical evaluation of the first adenosine A1 receptor partial agonist Radioligand for positron emission tomography imaging. J Med Chem 61:9966–9975PubMedCrossRefPubMedCentral
156.
Mead BP, Kim N, Miller GW et al (2017) Novel focused ultrasound gene therapy approach noninvasively restores dopaminergic neuron function in a rat Parkinson's disease model. Nano Lett 17:3533–3542PubMedPubMedCentralCrossRef
157.
Hua Y, Sahashi K, Rigo F et al (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478:123–126PubMedPubMedCentralCrossRef
158.
Tomiyama T, Matsuyama S, Iso H et al (2010) A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30:4845–4856PubMedPubMedCentralCrossRef
159.
Boronat-Garcia A, Palomero-Rivero M, Guerra-Crespo M et al (2016) Intrastriatal grafting of chromospheres: survival and functional effects in the 6-OHDA rat model of Parkinson's disease. PLoS One 11:e0160854PubMedPubMedCentralCrossRef
160.
Chow RD, Guzman CD, Wang G et al (2017) AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nat Neurosci 20:1329–1341PubMedPubMedCentralCrossRef
161.
162.
Lin H, Hu H, Duan W et al (2016) Intramuscular delivery of scAAV9-hIGF1 prolongs survival in the hSOD1(G93A) ALS mouse model via upregulation of D-amino acid oxidase. Mol Neurobiol
163.
de Solis CA, Ho A, Holehonnur R, Ploski JE (2016) The development of a viral mediated CRISPR/Cas9 system with doxycycline dependent gRNA expression for inducible in vitro and in vivo genome editing. Front Mol Neurosci 9:70PubMedPubMedCentralCrossRef
164.
Suzuki K, Tsunekawa Y, Hernandez-Benitez R et al (2016) In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. Nature 540:144–149PubMedPubMedCentralCrossRef
165.
Nishiyama J, Mikuni T, Yasuda R (2017) Virus-mediated genome editing via homology-directed repair in mitotic and postmitotic cells in mammalian brain. Neuron 96:755–768 e755PubMedPubMedCentralCrossRef
166.
Swiech L, Heidenreich M, Banerjee A et al (2015) In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 33:102–106PubMedCrossRef
167.
Back S, Necarsulmer J, Whitaker LR et al (2019) Neuron-specific genome modification in the adult rat brain using CRISPR-Cas9 transgenic rats. Neuron 102:105–119PubMedCrossRef
168.
169.
Whitworth KM, Lee K, Benne JA et al (2014) Use of the CRISPR/Cas9 system to produce genetically engineered pigs from in vitro-derived oocytes and embryos. Biol Reprod 91:1–13CrossRef
170.
Zhou X, Xin J, Fan N et al (2015) Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer. Cell Mol Life Sci 72:1175–1184PubMedCrossRef
171.
Niu Y, Shen B, Cui Y et al (2014) Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156:836–843PubMedCrossRef
172.
Ohmura Y, Tanaka KF, Tsunematsu T et al (2014) Optogenetic activation of serotonergic neurons enhances anxiety-like behaviour in mice. Int J Neuropsychopharmacol 17:1777–1783PubMedCrossRef
173.
Bock R, Shin JH, Kaplan AR et al (2013) Strengthening the accumbal indirect pathway promotes resilience to compulsive cocaine use. Nat Neurosci 16:632–638PubMedPubMedCentralCrossRef
174.
Krashes MJ, Shah BP, Koda S, Lowell BB (2013) Rapid versus delayed stimulation of feeding by the endogenously released AgRP neuron mediators GABA, NPY, and AgRP. Cell Metab 18:588–595PubMedCrossRef
175.
Cai H, Haubensak W, Anthony TE, Anderson DJ (2014) Central amygdala PKC-delta(+) neurons mediate the influence of multiple anorexigenic signals. Nat Neurosci 17:1240–1248PubMedPubMedCentralCrossRef
176.
177.
178.
Manvich DF, Webster KA, Foster SL et al (2018) The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice. Sci Rep-UK 8:3840CrossRef
179.
Mahler SV, Vazey EM, Beckley JT et al (2014) Designer receptors show role for ventral pallidum input to ventral tegmental area in cocaine seeking. Nat Neurosci 17:577–585PubMedPubMedCentralCrossRef
180.
Thompson KJ, Khajehali E, Bradley SJ et al (2018) DREADD agonist 21 is an effective agonist for muscarinic-based DREADDs in vitro and in vivo. ACS Pharmacol Trans Sci 1:61–72CrossRef
181.
Yuan P, Grutzendler J (2016) Attenuation of beta-amyloid deposition and neurotoxicity by chemogenetic modulation of neural activity. J Neurosci 36:632–641PubMedCrossRef
182.
Alcacer C, Andreoli L, Sebastianutto I et al (2017) Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy. J Clin Invest 127:720–734PubMedPubMedCentralCrossRef
183.
Chen Y, Xiong M, Dong Y et al (2016) Chemical control of grafted human PSC-derived neurons in a mouse model of Parkinson's disease. Cell Stem Cell 18:817–826PubMedPubMedCentralCrossRef
184.
Aldrin-Kirk P, Heuer A, Wang G et al (2016) DREADD modulation of transplanted DA neurons reveals a novel parkinsonian dyskinesia mechanism mediated by the serotonin 5-HT6 receptor. Neuron 90:955–968PubMedPubMedCentralCrossRef
185.
Michaelides M, Hurd YL (2015) DREAMM: a biobehavioral imaging methodology for dynamic in vivo whole-brain mapping of cell type-specific functional networks. Neuropsychopharmacol 40:239–240CrossRef
186.
Michaelides M, Anderson SA, Ananth M et al (2013) Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks. J Clin Invest 123:5342–5350PubMedPubMedCentralCrossRef
187.
Heneka MT, Ramanathan M, Jacobs AH et al (2006) Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 26:1343–1354PubMedPubMedCentralCrossRef
188.
Thanos PK, Taintor NB, Alexoff D et al (2002) In vivo comparative imaging of dopamine D2 knockout and wild-type mice with 11C-raclopride and microPET. J Nucl Med 43:1570–1577PubMed
189.
Brendel M, Jaworska A, Probst F et al (2016) Small-animal PET imaging of tau pathology with 18F-THK5117 in 2 transgenic mouse models. J Nucl Med 57:792–798PubMedCrossRef
190.
Manook A, Yousefi BH, Willuweit A et al (2012) Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One 7:e31310PubMedPubMedCentralCrossRef
191.
Brendel M, Jaworska A, Griessinger E et al (2015) Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models. PLoS One 10:e0116678PubMedPubMedCentralCrossRef
192.
Maier FC, Wehrl HF, Schmid AM et al (2014) Longitudinal PET-MRI reveals beta-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nat Med 20:1485–1492PubMedCrossRef
193.
Ghaemi M, Hilker R, Rudolf J et al (2002) Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 73:517–523PubMedPubMedCentralCrossRef
194.
Segovia F, Illan IA, Gorriz JM et al (2015) Distinguishing Parkinson's disease from atypical parkinsonian syndromes using PET data and a computer system based on support vector machines and Bayesian networks. Front Comput Neurosci 9:137PubMedPubMedCentralCrossRef
195.
Strome EM, Cepeda IL, Sossi V, Doudet DJ (2006) Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol Imaging Biol 8:292–299PubMedCrossRef
196.
Nikolaus S, Larisch R, Beu M et al (2003) Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur J Nucl Med Mol Imaging 30:390–395PubMedCrossRef
197.
Sharma SK, Ebadi M (2005) Distribution kinetics of 18F-DOPA in weaver mutant mice. Mol Brain Res 139:23–30PubMedCrossRef
198.
Antonini A, Leenders KL, Spiegel R et al (1996) Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119:2085–2095PubMedCrossRef
199.
Feigin A, Leenders KL, Moeller JR et al (2001) Metabolic network abnormalities in early Huntington's disease: an [18F]FDG PET study. J Nucl Med 42:1591–1595PubMed
200.
Araujo DM, Cherry SR, Tatsukawa KJ et al (2000) Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease. Exp Neurol 166:287–297PubMedCrossRef
201.
Kaneko G, Sanganahalli BG, Groman SM et al (2017) Hypofrontality and posterior hyperactivity in early schizophrenia: imaging and behavior in a preclinical model. Biol Psychiatry 81:503–513PubMedCrossRef
202.
Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367–1377PubMedCrossRef
203.
Lin LF, Doherty DH, Lile JD et al (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130–1132PubMedCrossRef
204.
Sullivan AM, Opacka-Juffry J, Blunt SB (1998) Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 10:57–63PubMedCrossRef
205.
Vandeputte C, Evens N, Toelen J et al (2011) A PET brain reporter gene system based on type 2 cannabinoid receptors. J Nucl Med 52:1102–1109PubMedCrossRef
206.
MacLaren DC, Gambhir SS, Satyamurthy N et al (1999) Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 6:785–791PubMedCrossRef
207.
Liang Q, Satyamurthy N, Barrio JR et al (2001) Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther 8:1490–1498PubMedCrossRef
208.
209.
Shao Y, Cherry SR, Farahani K et al (1997) Simultaneous PET and MR imaging. Phys Med Biol 42:1965–1970PubMedCrossRef
210.
Hammer BE, Christensen NL, Heil BG (1994) Use of a magnetic field to increase the spatial resolution of positron emission tomography. Med Phys 21:1917–1920PubMedCrossRef
211.
Pichler BJ, Lorenz E, Mirzoyan R, et al. (1997) Performance test of a LSO-APD PET module in a 9.4 Tesla magnet. In IEEE IEEE, pp 1237–1239
212.
Catana C, Procissi D, Wu Y et al (2008) Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci U S A 105:3705–3710PubMedPubMedCentralCrossRef
213.
Judenhofer MS, Wehrl HF, Newport DF et al (2008) Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 14:459–465PubMedCrossRef
214.
Wehrl HF, Hossain M, Lankes K et al (2013) Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales. Nat Med 19:1184–1189PubMedCrossRef
215.
Wehrl HF, Wiehr S, Divine MR et al (2014) Preclinical and translational PET/MR imaging. J Nucl Med 55:11s–18sPubMedCrossRef
216.
Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ (2009) Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging 36(Suppl 1):S56–S68PubMedCrossRef
217.
Sander CY, Hooker JM, Catana C et al (2013) Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proc Natl Acad Sci U S A 110:11169–11174PubMedPubMedCentralCrossRef
218.
Drzezga A, Arnold S, Minoshima S et al (1999) 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med 40:737–746PubMed
219.
Sabri O, Hellwig D, Schreckenberger M et al (1998) Correlation of neuropsychological, morphological and functional (regional cerebral blood flow and glucose utilization) findings in cerebral microangiopathy. J Nucl Med 39:147–154PubMed
220.
Ito S, Kato K, Ikeda M et al (2007) Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 48:889–895PubMedCrossRef
221.
Rominger A, Brendel M, Burgold S et al (2013) Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET. J Nucl Med 54:1127–1134PubMedCrossRef
222.
Liu Y, Zhu L, Plössl K et al (2010) Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease. Nucl Med Biol 37:917–925PubMedPubMedCentralCrossRef
223.
Snellman A, Rokka J, Lopez-Picon FR et al (2012) Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 39:1784–1795PubMedCrossRef
224.
Hostetler ED, Walji AM, Zeng Z et al (2016) Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med 57:1599–1606PubMedCrossRef
225.
Lohith T, Bennacef I, Sur C et al (2017) Quantification of [18F]MK-6240, a new PET tracer targeting human neurofibrillary tangles (NFTs) in brain of healthy elderly and subjects with Alzheimer’s disease. J Nucl Med 58:277–277
226.
W-d H, Herholz K (2006) Brain receptor imaging. J Nucl Med 47:302–312
227.
Nagano-Saito A, Lissemore JI, Gravel P, Leyton M, Carbonell F, Benkelfat C (2017) Posterior dopamine D2/3 receptors and brain network functional connectivity. Synapse e21993
228.
Constantinescu CC, Coleman RA, Pan ML, Mukherjee J (2011) Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [18F]fallypride and [18F]desmethoxyfallypride. Synapse 65:778–787PubMedPubMedCentralCrossRef
229.
Mukherjee J, Constantinescu CC, Hoang AT et al (2015) Dopamine D3 receptor binding of (18)F-fallypride: evaluation using in vitro and in vivo PET imaging studies. Synapse 69:577–591PubMedPubMedCentralCrossRef
230.
Kornum BR, Lind NM, Gillings N, Marner L, Andersen F, Knudsen GM (2009) Evaluation of the novel 5-HT4 receptor PET ligand [11C]SB207145 in the Gottingen minipig. J Cereb Blood Flow Metab 29:186–196PubMedCrossRef
231.
da Cunha-Bang S, Mc Mahon B, MacDonald Fisher P et al (2016) High trait aggression in men is associated with low 5-HT levels, as indexed by 5-HT 4 receptor binding. Soc Cogn Affect Neurosci 11:548–555PubMedPubMedCentralCrossRef
232.
Yang KC, Takano A, Halldin C, wr L (2018) Serotonin concentration enhancers at clinically relevant doses reduce [1’C]AZ10419369 binding to the 5-HT1B receptors in the nonhuman primate brain. Transl Psychiatry 8:132PubMedPubMedCentralCrossRef
233.
Deen M, Hansen HD, Hougaard A et al (2017) Low 5-HT 1B receptor binding in the migraine brain: a PET study. Cephalalgia 0:033310241769870
234.
Ishibashi K, Miura Y, Ishikawa K et al (2016) Relationship between type 1 metabotropic glutamate receptors and cerebellar ataxia. J Neurol 263:2179–2187PubMedCrossRef
235.
Li S, Cai Z, M-q Z et al (2017) A novel 18F-labeled kappa opioid receptor antagonist as PET radiotracer: synthesis and in vivo evaluation of 18F-LY2459989 in non-human primates. J Nucl Med 117:140–146
236.
237.
Dani M, Wood M, Mizoguchi R et al (2018) Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. Brain 141:2740–2754PubMed
238.
Datta G, Colasanti A, Rabiner EA et al (2017) Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. Brain 140:2927–2938PubMedCrossRef
239.
240.
Arakawa R, Farde L, Matsumoto J et al (2018) Potential effect of prolonged sevoflurane anesthesia on the kinetics of [11C]raclopride in non-human primates. Mol Imaging Biol 20:183–187PubMedCrossRef
241.
Hassoun W, Le Cavorsin M, Ginovart N et al (2003) PET study of the [18C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow. Eur J Nucl Med Mol Imaging 30:141–148PubMedCrossRef
242.
Chen Z, Tang J, Liu C et al (2016) Effects of anesthetics on vesicular monoamine transporter type 2 binding to 18F-FP-(+)-DTBZ: a biodistribution study in rat brain. Nucl Med Biol 43:124–129PubMedCrossRef
243.
Takuwa H, Maeda J, Ikoma Y et al (2015) [18C]Raclopride binding in the striatum of minimally restrained and free-walking awake mice in a positron emission tomography study. Synapse 69:600–606PubMedCrossRef
244.
Miranda A, Staelens S, Stroobants S, Verhaeghe J (2017) Fast and accurate rat head motion tracking with point sources for awake brain PET. IEEE Trans Med Imaging 36:1573–1582PubMedCrossRef
245.
Miranda A, Glorie D, Bertoglio D et al (2018) Awake 18F-FDG PET imaging of memantine-induced brain activation and test-retest in freely running mice. J Nucl Med 15
246.
Kyme AZ, Angelis GI, Eisenhuth J et al (2018) Open-field PET: simultaneous brain functional imaging and behavioural response measurements in freely moving small animals. Neuroimage 188:92–101PubMedCrossRef
247.
Egerton A, Modinos G, Ferrera D, McGuire P (2017) Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis. Transl Psychiatry 7:e1147PubMedPubMedCentralCrossRef
248.
Mannheim JG, Kara F, Doorduin J et al (2017) Standardization of small animal imaging—current status and future prospects. Mol Imaging Biol 20:716–731CrossRef
249.
Wu T, Grandjean J, Bosshard SC et al (2017) Altered regional connectivity reflecting effects of different anaesthesia protocols in the mouse brain. Neuroimage 149:190–199PubMedCrossRef
250.
Vanhoutte G, Verhoye M, Van der Linden A (2006) Changing body temperature affects the T2* signal in the rat brain and reveals hypothalamic activity. Magn Reson Med 55:1006–1012PubMedCrossRef
251.
Gillam JE, Angelis GI, Kyme AZ, Meikle SR (2017) Motion compensation using origin ensembles in awake small animal positron emission tomography. Phys Med Biol 62:715–733PubMedCrossRef
252.
Kyme AZ, Zhou VW, Meikle SR et al (2011) Optimised motion tracking for positron emission tomography studies of brain function in awake rats. PLoS One 6:e21727PubMedPubMedCentralCrossRef
Metadata
Title
Quantitative Rodent Brain Receptor Imaging
Authors
Kristina Herfert
Julia G. Mannheim
Laura Kuebler
Sabina Marciano
Mario Amend
Christoph Parl
Hanna Napieczynska
Florian M. Maier
Salvador Castaneda Vega
Bernd J. Pichler
Publication date
01-04-2020
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 2/2020
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-019-01368-9

Other articles of this Issue 2/2020

Molecular Imaging and Biology 2/2020 Go to the issue

Research Article

Acute Rodent Tolerability, Toxicity, and Radiation Dosimetry Estimates of the S1P1-Specific Radioligand [11C]CS1P1

Research Article

GABAA Receptors in the Mongolian Gerbil: a PET Study Using [18F]Flumazenil to Determine Receptor Binding in Young and Old Animals

Research Article

An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [18F]FP-(+)-DTBZ

Research Article

Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions

Special Topic

Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance

Research Article

Evaluating the Role of Amide Proton Transfer (APT)–Weighted Contrast, Optimized for Normalization and Region of Interest Selection, in Differentiation of Neoplastic and Infective Mass Lesions on 3T MRI